These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 27620302)

  • 1. Characterization of IL-17AA and IL-17FF in rheumatoid arthritis and multiple sclerosis.
    Schofield C; Fischer SK; Townsend MJ; Mosesova S; Peng K; Setiadi AF; Song A; Baruch A
    Bioanalysis; 2016 Nov; 8(22):2317-2327. PubMed ID: 27620302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF.
    DeForge LE; Loyet KM; Delarosa D; Chinn J; Zamanian F; Chuntharapai A; Lee J; Hass P; Wei N; Townsend MJ; Wang J; Wong WL
    J Immunol Methods; 2010 Oct; 362(1-2):70-81. PubMed ID: 20833179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of IL-17AA and IL-17FF as Pharmacodynamic Biomarkers to Demonstrate Target Engagement in the Phase I Study of MCAF5352A.
    Peng K; Wang Y; Siradze K; Erickson R; Fischer SK; Staton TL
    AAPS J; 2018 Dec; 21(1):9. PubMed ID: 30547287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational dynamics in interleukin 17A and 17F functional complexes is a key determinant of receptor A affinity and specificity.
    Waters LC; Veverka V; Strong SL; Muskett FW; Dedi N; Lawson ADG; Prosser CE; Taylor RJ; Henry AJ; Carr MD
    Cytokine; 2021 Jun; 142():155476. PubMed ID: 33706174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
    Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
    Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cells undergo unique compartmentalized redistribution in multiple sclerosis.
    Haas J; Bekeredjian-Ding I; Milkova M; Balint B; Schwarz A; Korporal M; Jarius S; Fritz B; Lorenz HM; Wildemann B
    J Autoimmun; 2011 Dec; 37(4):289-99. PubMed ID: 21924866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
    Bălaşa R; Bajko Z; Huţanu A
    Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated cerebrospinal fluid interleukin-17A and interferon-γ levels in early asymptomatic neurosyphilis.
    Pastuszczak M; Jakiela B; Wielowieyska-Szybinska D; Jaworek AK; Zeman J; Wojas-Pelc A
    Sex Transm Dis; 2013 Oct; 40(10):808-12. PubMed ID: 24275734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gingival crevicular fluid, serum levels of receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-17 in patients with rheumatoid arthritis and osteoporosis and with periodontal disease.
    Gümüş P; Buduneli E; Bıyıkoğlu B; Aksu K; Saraç F; Nile C; Lappin D; Buduneli N
    J Periodontol; 2013 Nov; 84(11):1627-37. PubMed ID: 23327689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis.
    Rentzos M; Cambouri C; Rombos A; Nikolaou C; Anagnostouli M; Tsoutsou A; Dimitrakopoulos A; Triantafyllou N; Vassilopoulos D
    J Neurol Sci; 2006 Feb; 241(1-2):25-9. PubMed ID: 16316662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients.
    Bartosik-Psujek H; Stelmasiak Z
    J Neural Transm (Vienna); 2005 Jun; 112(6):797-803. PubMed ID: 15480850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased IL-17A but decreased IL-27 serum levels in patients with multiple sclerosis.
    Babaloo Z; Yeganeh RK; Farhoodi M; Baradaran B; Bonyadi M; Aghebati L
    Iran J Immunol; 2013 Mar; 10(1):47-54. PubMed ID: 23502338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased IL-22 in cerebrospinal fluid of neuro-behçet's disease patients.
    Belghith M; Maghrebi O; Ben Laamari R; Hanachi M; Hrir S; Saied Z; Belal S; Driss A; Ben Sassi S; Boussoffara T; Barbouche MR
    Cytokine; 2024 Jul; 179():156617. PubMed ID: 38631183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis.
    Setiadi AF; Abbas AR; Jeet S; Wong K; Bischof A; Peng I; Lee J; Bremer M; Eggers EL; DeVoss J; Staton T; Herman A; von Büdingen HC; Townsend MJ
    J Neuroimmunol; 2019 Jul; 332():147-154. PubMed ID: 31034962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Influence of Polymorphisms of Interleukin-17A and -17F Genes on Susceptibility and Activity of Rheumatoid Arthritis.
    Erkol İnal E; Görükmez O; Dündar Ü; Görükmez Ö; Yener M; Özemri Sağ Ş; Yakut T
    Genet Test Mol Biomarkers; 2015 Aug; 19(8):461-4. PubMed ID: 26154773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-17 patterns in synovium, serum and synovial fluid from treatment-naïve, early rheumatoid arthritis patients.
    Roşu A; Mărgăritescu C; Stepan A; Muşetescu A; Ene M
    Rom J Morphol Embryol; 2012; 53(1):73-80. PubMed ID: 22395503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral inflammatory disease associated with centrally activated IL-1 system in humans and mice.
    Lampa J; Westman M; Kadetoff D; Agréus AN; Le Maître E; Gillis-Haegerstrand C; Andersson M; Khademi M; Corr M; Christianson CA; Delaney A; Yaksh TL; Kosek E; Svensson CI
    Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12728-33. PubMed ID: 22802629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micro-RNA 18b and interleukin 17A profiles in relapsing remitting multiple sclerosis.
    Mohamed MS; Nahrery EMAE; Shalaby N; Hussein M; Aal RAE; Mohamed MM
    Mult Scler Relat Disord; 2019 Feb; 28():226-229. PubMed ID: 30623862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders.
    Lebrun C; Cohen M; Pignolet B; Seitz-Polski B; Bucciarelli F; Benzaken S; Kantarci O; Siva A; Okuda D; Pelletier D; Brassat D; ;
    J Neurol Sci; 2016 Sep; 368():334-6. PubMed ID: 27538659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of endogenous IFN-β in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis.
    Tao Y; Zhang X; Chopra M; Kim MJ; Buch KR; Kong D; Jin J; Tang Y; Zhu H; Jewells V; Markovic-Plese S
    J Immunol; 2014 Jun; 192(12):5610-7. PubMed ID: 24850724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.